Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Current Oncology (Toronto, Ont.)|May 27, 2025
A Multi-Site Refinement Study of Taking Back Control Together, an Intervention to Support Parents Confronted with Childhood CancerNikita Guarascio, Ariane Levesque, David Ogez, et al.Journal of Clinical Medicine|December 23, 2022
COVID-19 and Sickle Cell Disease in the Province of Quebec, Canada: Outcomes after Two Years of the PandemicMathias Castonguay, Nawar Dakhallah, Justin Desroches, et al.Cancer Medicine|February 24, 2024
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in CanadaSandra Judd, Gabriel Revon-Riviere, Stephanie A Grover, et al.International Journal of Hematology|January 29, 2024
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironmentAlexandre Benoit, Madelyn J Abraham, Sheena Li, et al.Journal of Thrombosis and Haemostasis : JTH|December 18, 2024
Molecular signatures associated with venous thromboembolism in children with acute lymphoblastic leukemiaMarie-Claude Pelland-Marcotte, Anas Belaktib, Arnaud Droit, et al.British Journal of Haematology|May 21, 2020
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapyNicole A Carreau, Philippe Armand, Reid W Merryman, et al.Blood Advances|December 21, 2021
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001Thai Hoa Tran, Sylvie Langlois, Caroline Meloche, et al.The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.Blood Advances|September 20, 2023
CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216Verena Gress, Mathieu Roussy, Luc Boulianne, et al.Pageof 2